Join the Ocrevus group to help and get support from people like you.
Ocrevus News
Pharma Payments Might Influence MS Drug Prescriptions, Researchers Argue
THURSDAY, Sept. 18, 2025 — Nearly 4 out of 5 American neurologists prescribing multiple sclerosis (MS) drugs have received at least one payment from the pharmaceutical industry, a new study reports. T...
When Insurers Restrict MS Drug Coverage, Relapses Rise
TUESDAY, Aug. 5, 2025 — Multiple sclerosis (MS) patients might have a higher risk of relapse if their health insurance is stingy with prescriptions, a new study reports. Patients with insurance plans ...
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...
FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
South San Francisco, CA – December 14, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a...
FDA Approves Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
South San Francisco, CA – March 28, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Ocrevus...